[{"orgOrder":0,"company":"Centre Georges Fran\u00e7ois Leclerc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Chlortetracycline","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Centre Georges Fran\u00e7ois Leclerc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Georges Fran\u00e7ois Leclerc \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Centre Georges Fran\u00e7ois Leclerc \/ AstraZeneca"}]

Find Clinical Drug Pipeline Developments & Deals for Chlortetracycline

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Centre Georges François Leclerc

                          Country arrow
                          CPhI India
                          Not Confirmed

                          Centre Georges François Leclerc

                          Country arrow
                          CPhI India
                          Not Confirmed

                          Details : CTC is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 27, 2011

                          Lead Product(s) : Chlortetracycline

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank